David J. Salant

David J. Salant

Auto-generated profile, based on publicly available information

David J. Salant

Division of Nephrology, Department of Medicine, Boston University School of Medicine, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

55Years (1972-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
LBLaurence H. Jr. Beck
Laurence H. Jr. Beck
RBRamon G.B. Bonegio
Ramon G.B. Bonegio
GLGerard Lambeau
Gerard Lambeau
DBDavid M. Beck
David M. Beck
DPDavid W. Powell
David W. Powell
DSDavid J. Salant
David J. Salant
Idiopathic membranous nephropathy, a common form of the nephrotic syndrome, is an antibody-mediated autoimmune glomerular disease. Serologic diagnosis has been elusive because the target antigen is unknown. We performed Western blotting of protein extracts from normal human glomeruli with serum samples from patients with idiopathic or secondary membranous nephropathy or other proteinuric or autoimmune diseases and from normal controls. We used mass spectrometry to analyze the reactive protein bands and confirmed the identity and location of the target antigen with a monospecific antibody. Serum samples from 26 of 37 patients (70%) with idiopathic but not secondary membranous nephropathy specifically identified a 185-kD glycoprotein in nonreduced glomerular extract. Mass spectrometry of the reactive protein band detected the M-type phospholipase A2 receptor (PLA2R). Reactive serum specimens recognized recombinant PLA2R and bound the same 185-kD glomerular protein as did the monospecific anti-PLA2R antibody. Anti-PLA2R autoantibodies in serum samples from patients with membranous nephropathy were mainly IgG4, the predominant immunoglobulin subclass in glomerular deposits. PLA2R was expressed in podocytes in normal human glomeruli and colocalized with IgG4 in immune deposits in glomeruli of patients with membranous nephropathy. IgG eluted from such deposits in patients with idiopathic membranous nephropathy, but not in those with lupus membranous or IgA nephropathy, recognized PLA2R. A majority of patients with idiopathic membranous nephropathy have antibodies against a conformation-dependent epitope in PLA2R. PLA2R is present in normal podocytes and in immune deposits in patients with idiopathic membranous nephropathy, indicating that PLA2R is a major antigen in this disease.

11 December 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
NTNicola M. Tomas
Nicola M. Tomas
LBLaurence H. Jr. Beck
Laurence H. Jr. Beck
CMCatherine Meyer-Schwesinger
Catherine Meyer-Schwesinger
BSBarbara Seitz-Polski
Barbara Seitz-Polski
HMHong Ma
Hong Ma
GLGerard Lambeau
Gerard Lambeau
Idiopathic membranous nephropathy is an autoimmune disease. In approximately 70% of patients, it is associated with autoantibodies against the phospholipase A2 receptor 1 (PLA2R1). Antigenic targets in the remaining patients are unknown. Using Western blotting, we screened serum samples from patients with idiopathic membranous nephropathy, patients with other glomerular diseases, and healthy controls for antibodies against human native glomerular proteins. We partially purified a putative new antigen, identified this protein by means of mass spectrometry of digested peptides, and validated the results by analysis of recombinant protein expression, immunoprecipitation, and immunohistochemical analysis. Serum samples from 6 of 44 patients in a European cohort and 9 of 110 patients in a Boston cohort with anti-PLA2R1–negative idiopathic membranous nephropathy recognized a glomerular protein that was 250 kD in size. None of the serum samples from the 74 patients with idiopathic membranous nephropathy who were seropositive for anti-PLA2R1 antibodies, from the 76 patients with other glomerular diseases, and from the 44 healthy controls reacted against this antigen. Although this newly identified antigen is clearly different from PLA2R1, it shares some biochemical features, such as N-glycosylation, membranous location, and reactivity with serum only under nonreducing conditions. Mass spectrometry identified this antigen as thrombospondin type-1 domain-containing 7A (THSD7A). All reactive serum samples recognized recombinant THSD7A and immunoprecipitated THSD7A from glomerular lysates. Moreover, immunohistochemical analyses of biopsy samples from patients revealed localization of THSD7A to podocytes, and IgG eluted from one of these samples was specific for THSD7A. In our cohort, 15 of 154 patients with idiopathic membranous nephropathy had circulating autoantibodies to THSD7A but not to PLA2R1, a finding that suggests a distinct subgroup of patients with this condition. (Funded by the French National Center for Scientific Research and others.)

25 April 2010 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
WBWibke Bechtel-Walz
Wibke Bechtel-Walz
SMScott McGoohan
Scott McGoohan
EZElisabeth M Zeisberg
Elisabeth M Zeisberg
GMGerhard A Müller
Gerhard A Müller
HKHubert Kalbacher
Hubert Kalbacher
MZMichael Zeisberg
Michael Zeisberg

19 January 2006
Verified
Dataset
Closed access
DSDavid Salant
David Salant
LBLaurence Beck
Laurence Beck
Podocytes are highly specialized cells of the kidney glomerulus that wrap around capillaries and that neighbor cells of the Bowman’s capsule. Podocyte function depends on highly ordered cellular arrangement of filtration compartments and the correct signaling within this microenvironment. Therefore, podocytes are uniquely sensitive to a variety of agents interfering with their actin cytoskeleton, apical membrane domain (i.e. the negative surface charge)...

1 August 2011 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
LBLaurence H. Beck
Laurence H. Beck
FFFernando C. Fervenza
Fernando C. Fervenza
DBDavid M. Beck
David M. Beck
RBRamon G.B. Bonegio
Ramon G.B. Bonegio
FMFahim A. Malik
Fahim A. Malik
DSDavid J. Salant
David J. Salant
Autoantibodies to the M-type phospholipase A2 receptor (PLA2R) are sensitive and specific for idiopathic membranous nephropathy. The anti-B cell agent rituximab is a promising therapy for this disease, but biomarkers of early response to treatment currently do not exist. Here, we investigated whether levels of anti-PLA2R correlate with the immunological activity of membranous nephropathy, potentially exhibiting a more rapid response to treatment than clinical parameters such as proteinuria. We measured the amount of anti-PLA2R using Western blot immunoassay in serial serum samples from a total of 35 patients treated with rituximab for membranous nephropathy in two distinct cohorts. Pretreatment samples from 25 of 35 (71%) patients contained anti-PLA2R, and these autoantibodies declined or disappeared in 17 (68%) of these patients within 12 months after rituximab. Those who demonstrated this immunologic response fared better clinically: 59% and 88% attained complete or partial remission by 12 and 24 months, respectively, compared with 0% and 33% among those with persistent anti-PLA2R levels. Changes in antibody levels preceded changes in proteinuria. One subject who relapsed during follow-up had a concomitant return of anti-PLA2R. In summary, measuring anti-PLA2R levels by immunoassay may be a method to follow and predict response to treatment with rituximab in membranous nephropathy.

7 April 1997 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CLClare M. Lloyd
Clare M. Lloyd
AMAndrew W. Minto
Andrew W. Minto
MDMartin E. Dorf
Martin E. Dorf
APAmanda Proudfoot
Amanda Proudfoot
TWTimothy N. C Wells
Timothy N. C Wells
JGJose-Carlos Gutierrez-Ramos
Jose-Carlos Gutierrez-Ramos
The involvement of chemokines in inflammation is well established, but their functional role in disease progression, and particularly in the development of fibrosis, is not yet understood. To investigate the functional role that the chemokines monocyte chemoattractant protein–1 (MCP-1) and RANTES play in inflammation and the progression to fibrosis during crescentic nephritis we have developed and characterized a murine model for this syndrome. Significant increases in T-lymphocytes and macrophages were observed within glomeruli and interstitium, paralleled by an induction of mRNA expression of MCP-1 and RANTES, early after disease initiation. Blocking the function of MCP-1 or RANTES resulted in significant decreases in proteinuria as well as in numbers of infiltrating leukocytes, indicating that both MCP-1 and RANTES (regulated upon activation in normal T cells expressed and secreted) play an important role in the inflammatory phase of crescentic nephritis. In addition, neutralization of MCP-1 resulted in a dramatic decrease in both glomerular crescent formation and deposition of type I collagen. These results highlight a novel role for MCP-1 in crescent formation and development of interstitial fibrosis, and indicate that in addition to recruiting inflammatory cells this chemokine is critically involved in irreversible tissue damage.